RxDoctor Payments Data

Brian Jaski, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1194706242

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $203,127 of the $234,770 with a category attached, or 86.5%. Boston Scientific accounts for 86.7% of it on its own, with 48 other manufacturers making up the rest. Among advanced heart failure and transplant cardiology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$234,770in general payments, 2019–2025

Across 702 payments — averaging $334.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$204K
  • Nuwellis, Inc.$11K
  • Abbott$9K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Novartis$1K
  • Abiomed$1K
  • plus $7K from 43 others
$427,502in research payments, 2019–2025

Across 60 payments — averaging $7125.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$290K
  • Abbott$111K
  • Nuwellis, Inc.$27K

What the payments were for

  • Consulting fees$203,12787%
  • Speaking & faculty fees$13,5006%
  • Travel & lodging$3,4021%
  • Food & beverage$14,7296%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$234,770 in reported general payments places this provider in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$326,300
Medicare patients
1,126
Services billed
3,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$193,791
EntrestoSacubitril/Valsartan117$182,201
XareltoRivaroxaban77$105,748
JardianceEmpagliflozin55$75,069
FarxigaDapagliflozin Propanediol75$64,042
Repatha SureclickEvolocumab21$35,419
BrilintaTicagrelor18$13,482
EdarbiAzilsartan Medoxomil18$11,677
Ezetimibe123$4,826
Ranolazine ErRanolazine19$3,629
Rosuvastatin Calcium188$3,461
Metoprolol Succinate182$3,069
Atorvastatin Calcium253$2,548
Digoxin41$2,257
Olmesartan Medoxomil81$2,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$529$193,791145 claims
NovartisEntresto$1,375$182,201117 claims
Johnson & JohnsonXarelto$176$105,74877 claims
AstraZenecaFarxiga, Brilinta$546$77,52393 claims
Boehringer IngelheimJardiance$179$75,06955 claims
Arbor Pharmaceuticals, Inc.Edarbi$13$11,67718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →